Furthermore, LAMP3 expression levels are significantly higher in patients with NSCLC who undergo neoadjuvant immunochemotherapy compared to untreated patients, underscoring the involvement of LAMP3+ DCs in actively regulating the therapeutic response to neoadjuvant immunochemotherapy [44]. This evidence concerns the gene LAMP3 and non-small cell lung carcinoma.